JP2022523819A5 - - Google Patents

Info

Publication number
JP2022523819A5
JP2022523819A5 JP2021552742A JP2021552742A JP2022523819A5 JP 2022523819 A5 JP2022523819 A5 JP 2022523819A5 JP 2021552742 A JP2021552742 A JP 2021552742A JP 2021552742 A JP2021552742 A JP 2021552742A JP 2022523819 A5 JP2022523819 A5 JP 2022523819A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oil
pharmaceutically acceptable
abiraterone
decanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552742A
Other languages
English (en)
Japanese (ja)
Other versions
JP7644713B2 (ja
JP2022523819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020915 external-priority patent/WO2020180942A1/en
Publication of JP2022523819A publication Critical patent/JP2022523819A/ja
Publication of JP2022523819A5 publication Critical patent/JP2022523819A5/ja
Application granted granted Critical
Publication of JP7644713B2 publication Critical patent/JP7644713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552742A 2019-03-06 2020-03-04 アビラテロンプロドラッグ Active JP7644713B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814568P 2019-03-06 2019-03-06
US62/814,568 2019-03-06
US201962849259P 2019-05-17 2019-05-17
US62/849,259 2019-05-17
PCT/US2020/020915 WO2020180942A1 (en) 2019-03-06 2020-03-04 Abiraterone prodrugs

Publications (3)

Publication Number Publication Date
JP2022523819A JP2022523819A (ja) 2022-04-26
JP2022523819A5 true JP2022523819A5 (https=) 2023-03-09
JP7644713B2 JP7644713B2 (ja) 2025-03-12

Family

ID=70190090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552742A Active JP7644713B2 (ja) 2019-03-06 2020-03-04 アビラテロンプロドラッグ

Country Status (15)

Country Link
US (4) US10792292B2 (https=)
EP (2) EP4286006A3 (https=)
JP (1) JP7644713B2 (https=)
KR (1) KR102879575B1 (https=)
CN (3) CN114026106B (https=)
AU (1) AU2020232706B2 (https=)
BR (1) BR112021017377A2 (https=)
CA (1) CA3131034A1 (https=)
DK (1) DK3935068T3 (https=)
ES (1) ES2964818T3 (https=)
IL (1) IL286048B2 (https=)
MX (1) MX2021010553A (https=)
PL (1) PL3935068T3 (https=)
WO (1) WO2020180942A1 (https=)
ZA (1) ZA202107278B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) * 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
US12347562B2 (en) * 2019-12-26 2025-07-01 Cerner Innovation, Inc. Decision support application for PCOS
CN116490165A (zh) * 2020-09-02 2023-07-25 普洛佩拉治疗公司 阿比特龙前药
CN113929727A (zh) * 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
US11957696B2 (en) * 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
CN113061154B (zh) * 2021-03-25 2022-07-08 天津海润家和创新医药研究有限责任公司 新型注射用阿比特龙衍生物的制备方法和用途
CN113527401A (zh) * 2021-08-26 2021-10-22 雷昊言 一种阿比特龙前体化合物及其制备方法和应用
JP2024533332A (ja) 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤
CA3243913A1 (en) 2022-03-01 2023-09-07 Astellas Us Llc Abiraterone prodrugs
WO2024107928A1 (en) 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116046950A (zh) * 2023-01-18 2023-05-02 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) 一种检测醋酸阿比特龙中5种杂质的方法
LU506495B1 (en) * 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
AU2003211877A1 (en) 2002-03-11 2003-09-22 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
TW200404552A (en) 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
EP1890677A4 (en) * 2005-06-16 2013-01-30 Myriad Genetics Inc PHARMACEUTICAL COMPOSITIONS AND THEIR USE
PL2478907T3 (pl) * 2006-08-25 2021-10-25 Janssen Oncology, Inc. Kompozycje do leczenia nowotworu
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
CN102686600A (zh) * 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
CA2782266A1 (en) 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
WO2011083830A1 (ja) * 2010-01-06 2011-07-14 学校法人関西文理総合学園 新規抗がん剤およびそのスクリーニング方法
EP2651916A2 (en) 2010-12-16 2013-10-23 BioMarin Pharmaceutical Inc. C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN104066744B (zh) 2011-10-10 2017-03-22 扎克系统公司 用于制备17‑取代的甾体的方法
HRP20191982T4 (hr) 2011-11-30 2023-01-06 Astrazeneca Ab Kombinacijsko liječenje raka
US20150005265A1 (en) 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP2841444A4 (en) 2012-04-23 2015-11-04 Alphora Res Inc PROCESS FOR PREPARING 17-SUBSTITUTED STEROIDS
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014016830A1 (en) 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
US20140011992A1 (en) 2012-12-20 2014-01-09 Crystal Pharma, S.A.U. Synthesis of abiraterone and related compounds
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
WO2014111815A2 (en) * 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
US20140287039A1 (en) 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN109806266A (zh) 2013-10-01 2019-05-28 诺华股份有限公司 用于癌症治疗的组合及其应用
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
CN104017045B (zh) * 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US9937259B2 (en) * 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
SG11201701139YA (en) 2014-09-18 2017-03-30 Iceutica Inc Abiraterone acetate formulation and methods of use
CN104356191A (zh) 2014-09-29 2015-02-18 上海延安药业（湖北）有限公司 阿比特龙单琥珀酸酯及其制备方法
CN106061990B (zh) 2014-11-28 2019-09-10 四川海思科制药有限公司 一种阿比特龙衍生物及其制备方法和医药用途
CN104447394B (zh) * 2014-12-17 2017-01-18 成都傲飞生物化学品有限责任公司 一种乌苯美司的新型合成工艺
CN104710499A (zh) * 2015-02-15 2015-06-17 重庆医药工业研究院有限责任公司 一种丙酸阿比特龙的晶型及其制备方法
MX2017011237A (es) * 2015-03-06 2017-11-28 Cleveland Clinic Found Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
EP3394080B1 (en) * 2015-12-23 2023-06-07 The University Of British Columbia Lipid-linked prodrugs
CN108541255B (zh) 2016-02-02 2019-06-14 深圳市塔吉瑞生物医药有限公司 一种甾体类化合物及包含该化合物的组合物及其用途
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
US10717762B2 (en) 2016-10-11 2020-07-21 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivative and formulations thereof
CN106977577A (zh) 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
EP3914234A4 (en) 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
AU2020240017A1 (en) 2019-03-18 2021-11-04 AustinPx, LLC Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
CN116490165A (zh) 2020-09-02 2023-07-25 普洛佩拉治疗公司 阿比特龙前药
CN113929727A (zh) 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
JP2024533332A (ja) 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤

Similar Documents

Publication Publication Date Title
JP2022523819A5 (https=)
IL286048B1 (en) Abiraterone decanoate and pharmaceutically acceptable salts thereof, pharmaceutical compsitions comprising the same, uses and preparation thereof
WO2012116290A2 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
JP7064772B2 (ja) 選択的エストロゲン受容体ダウンレギュレーター（ｓｅｒｄｓ）
TWI641616B (zh) 阿比特龍衍生物及其製備方法和醫藥用途
JP2024506382A5 (https=)
US11111227B2 (en) Rotigotine behenate, and manufacturing method and application thereof
US20030092638A1 (en) Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
WO2014127201A1 (en) Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for gaba type-a receptors
JP2018138594A (ja) オナプリストン多形体及び使用方法
JP2021522306A (ja) ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
WO2012134446A1 (en) Epiandrosterone and/or androsterone derivatives and method of use thereof
CN113929727A (zh) 阿比特龙酯类衍生物及其制备方法和应用
JP2014516078A (ja) 新規なタッカロノリド微小管安定剤
JPS6341887B2 (https=)
CA2626627C (en) Androsterone derivatives and method of use thereof
RU2021128701A (ru) Пролекарства абиратерона
CN1893955A (zh) 用于预防和治疗激素依赖性疾病的包含孕酮受体拮抗剂和纯抗雌激素的组合物
WO2014169462A1 (zh) 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法
US20030069215A1 (en) Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
TW200904451A (en) Progesterone-receptor antagonist for use in BRCA alone or as combination with antiestrogen
CN112341514B (zh) 脱氧胆酸类化合物、药物组合物及其用途
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
RU2719457C2 (ru) Сложные эфиры стероидного лактама и производных бис(2-хлорэтил)аминофеноксипропановой кислоты
CN103664836B (zh) 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法